Investor Presentaiton

Building IRIDEX to Leverage Market Expansion Opportunity Fiscal 2019-2020 Product and Technology Release and successful launch of Rev2 MP3 probe FDA clearance of new system platform project Release of two versions of LIO critically needed to address customer needs Updates to TxCell scanner product New Leadership and Domain Expertise In the past 12 months the executive team under a new CEO has managed a significant transition of Iridex, both strategically and tactically 4 Margin and Cost Implemented operational improvements to significantly reduce costs and increase efficiencies Net Cash usage in 9 months of 2020 of only $0.7M, despite COVID-driven revenue decline of 24% vs prior period Operational Execution Managed through COVID environment, both in field execution and internal remote work environment, to limit delays and continue strategic execution IRIDEX

View entire presentation